alternative asset manager The Carlyle Group
(NASDAQ:CG) today announced that Dr. Martin D. Madaus will become Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics (“OCD”) subject to the close of Carlyle’s acquisition of OCD from Johnson & Johnson, which is expected in mid-2014. Eric Compton, OCD Worldwide President, will continue with the company following the close of the transaction.
Introduced to OCD today during a global employee meeting, Dr. Madaus said, “I am pleased by the opportunity to join Ortho-Clinical Diagnostics and look forward to working with such a talented group of professionals around the world. I am excited at the prospect of leading the organization through its next phase of growth, driven by new product innovation and geographic expansion. Eric and his team have accomplished great things as part of Johnson & Johnson and I look forward to helping transform OCD into a global diagnostics leader as a standalone entity.”
Eric Compton, OCD Worldwide President, said, “OCD has made strategic investments in research and development programs over the past few years and the Company is poised for continued success in the future. Together with Martin and the team at Carlyle, we believe OCD is positioned to accelerate growth globally through new product introductions.”
Stephen H. Wise, Carlyle Managing Director, said, “As an experienced executive with an exemplary track record of growing businesses, Martin can lead OCD through its transition to an independent company and transformation into a leading diagnostics platform. We believe our long-term partnership with Martin in the in vitro diagnostics industry will create significant value for our investors over the coming years.”
Dr. Madaus is the current Executive Chairman of Quanterix’s Board of Directors. He most recently served as President, Chairman and Chief Executive Officer of Millipore Corp., which was acquired by Merck KGaA in 2010. Before joining Millipore, Dr. Madaus was President, Chief Executive Officer and Head of North American Operations for Roche Diagnostics Corp.